Case Report Documents Unexpected Acute Pancreatitis After Tarlatamab

Tarlatamab, a bispecific T-cell engager approved for relapsed extensive-stage small cell lung cancer, has shown significant clinical activity alongside notable toxicity rates. A recent multi-institutional real-world analysis identified predictive biomarkers for cytokine release syndrome and neurotoxicity, while a separate case report documented unexpected acute pancreatitis following administration.

Recent clinical evaluations of tarlatamab—marketed as Imdelltra—highlight both its therapeutic potential in treating relapsed extensive-stage small cell lung cancer and the complex spectrum of immune-related side effects tied to its mechanism as a bispecific T-cell engager targeting delta-like ligand 3 on tumor cells and CD3 on T lymphocytes. As clinicians gain more experience with the therapy outside of controlled trials, accumulating real-world data is refining how medical teams assess patient risk, manage adverse reactions, and approach subsequent treatment cycles.

A multi-institutional real-world analysis evaluated 115 patients with extensive-stage small cell lung cancer who received tarlatamab receiving tarlatamab to understand the factors driving treatment response and toxicity. The study reported an overall response rate of 44% and a disease control rate of 58.2%, with six-month progression-free survival and overall survival standing at 30.4% and 54.9%, respectively. Researchers also noted specific rates for observed adverse events among the cohort, recording cytokine release syndrome at 46%, immune effector cell associated neurotoxicity syndrome at 28%, and dysgeusia at 47%.

Predictive markers of response and toxicity to tarlatamab in

While cytokine release syndrome and neurotoxicity remain the primary well-documented immune-related adverse effects of the drug, individual case reports are expanding the recognized toxicity profile.

developed severe epigastric pain on cycle 1, day 1 approximately eight hours after his initial dose.

Unexpected Acute Pancreatitis After Tarlatamab in Small Cell Lung

Medical evaluations confirmed acute interstitial pancreatitis through imaging alongside a sharply elevated serum lipase level of 781 U/L and a white blood cell count of 12.4 × 10⁹/L. Extensive diagnostic workups ruled out alternative etiologies, including alcohol use history, gallstones, biliary obstruction, hypertriglyceridemia, hypercalcemia, and autoimmune conditions like IgG4-related disease. Pancreatic metastasis from small cell lung cancer was also excluded via imaging.

The temporal proximity between drug administration and symptom onset supported a causal association driven by cytokine-mediated inflammation, echoing rare pancreatitis events seen with other T-cell-engaging therapies like blinatumomab and immune checkpoint inhibitors. Following supportive care, the patient recovered and successfully completed the remaining scheduled doses of cycle 1 on days 8 and 15 without a recurrence of symptoms or pancreatic enzyme elevations.

These findings collectively emphasize the necessity for clinicians to remain vigilant across multiple organ systems when administering tarlatamab.

The development of validated risk stratification tools offers a structured pathway to identify patients at high risk for significant inflammatory complications before treatment begins. At the same time, evidence that patients can successfully resume scheduled dosing after recovering from acute, transient adverse events suggests that clinicians can individualize rechallenge decisions once common alternative causes are thoroughly excluded.